Market Overview

Tricida Post-IPO Run-up Makes Goldman Wary

Share:
Related
The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs
48 Biggest Movers From Yesterday

Tricida Inc (NASDAQ: TCDA) shares have gained about 13.5 percent since their listing on June 28, on top of the nearly 37 percent gain made on the debut.

The Analyst

Citing the strong run up, Goldman Sachs analyst Dana Flanders initiated coverage on Tricida with a Neutral rating and a $32 price target.

The Thesis

Tricida's TRC101, a non-absorbed polymer meant to treat metabolic acidosis disease that accelerates the progression of chronic kidney disease, addresses a high unmet need, given there are no prior FDA-approved therapies for it and the current treatment options are contraindicated in most CKD patients due to co-morbidities, Flanders said in a Monday note.

The analyst estimates long-term risk-adjusted sales of $1.2 billion for TRC101, with a sales potential of $639 million by 2025. The analyst sees a list price of $18,000, with low-single-digit price increases over time. The treatment candidate is likely to be approved under the accelerated pathway in 2020, the analyst said.

Flanders sees potential for an inflection in uptake of TRC101 to mid-teens market share of mild-to-severe MA patients on positive outcomes data in 2022. This could also drive M&A interest in Tricida.

Price Action

Shares closed Monday at $29.25, down 0.8 percent.

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus

Latest Ratings for TCDA

DateFirmActionFromTo
Jul 2018Goldman SachsInitiates Coverage OnNeutral
Jul 2018JP MorganInitiates Coverage OnNeutral
Jul 2018Cowen & Co.Initiates Coverage OnOutperform

View More Analyst Ratings for TCDA
View the Latest Analyst Ratings

Posted-In: Dana Flanders Goldman SachsAnalyst Color Initiation Analyst Ratings

 

Related Articles (TCDA)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LXFTKeyBancDowngrades0.0
CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Earnings Preview: TransUnion

PACCAR's Q2 Earnings Outlook